TFRC and neoplasm: CALLA-01, a targeted NP system, consists of cyclodextrin-containing polymer, polyethylene glycol (PEG), human transferrin as a targeting ligand for binding transferrin receptors, and siRNA designed to reduce expression of RPM2 for tumor inhibition and/or tumor size reduction.